Literature DB >> 20359813

Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways.

Asmae Karroum1, Pezhman Mirshahi, Nadia Benabbou, Anne-Marie Faussat, Jeannette Soria, Amu Therwath, Massoud Mirshahi, Mohamed Hatmi.   

Abstract

Matrix metalloproteinase-9 (MMP-9) strongly influences tumor development and metastasis. Using resistant (rMCF-7) and sensitive (sMCF-7) breast cancer lines we investigated the role of MMP-9 in cell migration (CM) and tubular network (TN) formation, two processes implied in tumor growth and metastasis. Our data demonstrate that MMP-9 which is critical for CM is necessary but not sufficient for TN formation and suggest a link between MDR1/P-gp and constitutive MMP-9. Both TN formation and CM are dependent on PKC and ERK1/2 pathways. This study reinforces the logic of combining therefore MMP inhibitors in cancer therapy, especially in patients with chemoresistance and invasion/metastasis. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20359813     DOI: 10.1016/j.canlet.2010.03.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  Protein kinase C regulates ezrin-radixin-moesin phosphorylation in canine osteosarcoma cells.

Authors:  S-H Hong; T Osborne; L Ren; J Briggs; C Mazcko; S S Burkett; C Khanna
Journal:  Vet Comp Oncol       Date:  2010-12-14       Impact factor: 2.613

2.  Acquisition of paclitaxel resistance modulates the biological traits of gastric cancer AGS cells and facilitates epithelial to mesenchymal transition and angiogenesis.

Authors:  Ali Niapour; Naisana Seyedasli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-02-05       Impact factor: 3.000

Review 3.  The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers.

Authors:  Ying Shao; Bingjian Lu
Journal:  Cancer Metastasis Rev       Date:  2021-10-18       Impact factor: 9.264

4.  Role of P-glycoprotein on CD69+CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy.

Authors:  Shizuyo Tsujimura; Tomoko Adachi; Kazuyoshi Saito; Yoshiya Tanaka
Journal:  RMD Open       Date:  2017-07-14

5.  Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion.

Authors:  Liqiang Ma; Fenghua Lan; Zhiyong Zheng; Feilai Xie; Lie Wang; Wei Liu; Junyong Han; Feng Zheng; Yanchuan Xie; Qiaojia Huang
Journal:  Mol Cancer       Date:  2012-10-21       Impact factor: 27.401

6.  Downregulation of CD9 in keratinocyte contributes to cell migration via upregulation of matrix metalloproteinase-9.

Authors:  Xu-pin Jiang; Dong-xia Zhang; Miao Teng; Qiong Zhang; Jia-ping Zhang; Yue-sheng Huang
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

7.  The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy.

Authors:  Ying Liu; Wei Cao; Bo Zhang; Yong-qiang Liu; Zhong-yuan Wang; Yan-ping Wu; Xian-Jun Yu; Xu-dong Zhang; Ping-hong Ming; Guang-biao Zhou; Laiqiang Huang
Journal:  Sci Rep       Date:  2013-11-14       Impact factor: 4.379

8.  Hypoxia regulates CD9-mediated keratinocyte migration via the P38/MAPK pathway.

Authors:  Xupin Jiang; Xiaowei Guo; Xue Xu; Miao Teng; Chong Huang; Dongxia Zhang; Qiong Zhang; Jiaping Zhang; Yuesheng Huang
Journal:  Sci Rep       Date:  2014-09-09       Impact factor: 4.379

9.  Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC‑α/ERK1/2 pathway: An in vitro investigation.

Authors:  Xu-Dong Cheng; Jun-Fei Gu; Jia-Rui Yuan; Liang Feng; Xiao-Bin Jia
Journal:  Mol Med Rep       Date:  2015-10-15       Impact factor: 2.952

10.  Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells.

Authors:  Fei Zhang; Zhiyong Wang; Yanling Fan; Qiao Xu; Wei Ji; Ran Tian; Ruifang Niu
Journal:  Int J Mol Sci       Date:  2015-10-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.